XPHYF - XPHYF STOCK NEWS

XPhyto Therapeutics Corp. has announced significant progress in its drug formulation and development operations. Key developments include advancements in the Rotigotine transdermal patch optimization, with a pivotal study planned for Q2 2022. The company is also preparing for manufacturing, sales, and marketing initiatives. Additionally, cannabinoid oral dissolvable films are set for pilot studies, enhancing its product pipeline. The global transdermal skin patches market is projected to grow from US$6.5 billion in 2020 to US$9.39 billion by 2030, indicating strong market potential for XPhyto's innovative solutions.

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF, FSE:4XT) has extended its investor relations agreements with Knox Communications Inc. and M. Davis & Associates Capital Inc. for another 12 months, effective October 1, 2021. KCI will receive 100,000 options and a monthly fee of C$4,000, while Davis will be granted 200,000 options, 140,000 common shares, and a monthly compensation of C$10,000. Both consultants will assist XPhyto in marketing and investor communications strategies as the company focuses on its bioscience initiatives across North America and Europe.

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) announced the successful market launch of its COVID-ID Lab, a rapid 25-minute PCR test for COVID-19. The pilot project in Berlin optimized operational protocols, paving the way for sales growth. The test does not require RNA extraction, enabling quicker results. Demand for PCR testing is increasing as regulations shift from antigen to PCR tests across Germany and Europe. XPhyto is developing modular testing solutions for large events, enhancing safety while positioning itself competitively in the market.

XPhyto Therapeutics Corp. has successfully registered its first biosensor test for oral inflammation with German authorities, enabling at-home self-checks without medical training. The test dissolves on the tongue and indicates inflammation within five minutes by releasing a bitter taste. This registration marks a significant milestone in XPhyto's collaboration with 3a-diagnostics GmbH, highlighting the potential of biosensors in early disease detection. The global biosensor market is projected to grow to USD 38.7 billion by 2027, providing ample opportunity for commercial expansion.

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has identified the first saliva-activated biosensor candidates for COVID-19 diagnostics through its acquisition target, 3a-diagnostics GmbH. This innovation aims to provide a low-cost, real-time testing solution for infectious diseases, addressing the urgent global need for efficient diagnostics. The acquisition agreement, initially announced on July 20, 2021, involves a total payment of EUR 3.9 million. This advancement is a crucial step in enhancing XPhyto's diagnostic product pipeline.

XPhyto Therapeutics Corp. has announced its acquisition of 3a-diagnostics GmbH for a total of EUR 3.9 million, enhancing its diagnostic product portfolio. The deal secures a research and development team and a pipeline of ready-to-launch biosensor products. With the biosensor market expected to reach $42 billion by 2028, this acquisition provides XPhyto with significant commercial development opportunities. The merger aims to lead to improved profit margins and expedite commercialization of products, including the recently approved COVID-ID Lab test.

XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) announced the issuance of 7.957 common shares to AGORA Internet Relations Corp. for advertising services, priced at $2.13 per share, on June 17, 2021. AGORA will receive additional shares on August 31 and December 31, 2021. Post-issuance, AGORA holds 20,549 shares, equating to 0.03% of XPhyto's total shares. The company focuses on innovative drug delivery and diagnostics, seeking regulatory approval for its products in Europe.

XPhyto Therapeutics Corp. has signed a master supply agreement with Beovita GmbH & Co. KG and Tackleberries GmbH to provide around 1,000 rapid PCR COVID-19 tests to ten test centers in Berlin, Germany. The tests will be processed on-site, allowing for quicker results compared to traditional methods. This collaboration marks a significant milestone for XPhyto as it aims to meet the rising demand for efficient COVID-19 testing, particularly in high-traffic areas. Commercial operations are expected to begin with the delivery of test kits, and the company anticipates strong market demand for its Covid-ID Lab.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) has launched a 25-minute COVID-19 RT-PCR test, gaining CE-IVD approval and focusing on commercialization in Germany and Austria. CEO Hugh Rogers highlighted the company’s ability to rapidly take products from conception to market within ten months. XPhyto is also expanding its drug formulation program through the acquisition of Vektor Pharma TF, planning multiple pilot studies including one for a Parkinson's treatment. Rogers emphasized a strong operational strategy and a robust product pipeline.